Response to treatment with nab-Sirolimus in patients with perivascular epithelioid cell sarcoma of gynecologic or peritoneal origin: Subgroup analysis from AMPECT

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.063

Thomas Herzog , Lauren Dockery , Mark Dickson , Kristen Ganjoo , Vinod Ravi , Li Ding , Anita Schmid , Norma Palma , Willis Navarro , Andrew Wagner

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

妇科或腹膜源性血管周围上皮样细胞肉瘤患者对纳博-西罗莫司治疗的反应：AMPECT分组分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy

期刊最新文献

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial. Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer. Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months KRAS mutations in endometrial cancers: Possible prognostic and treatment implications